Philips launches HyperVue Integrated System in the U.S., bringing advanced coronary imaging and physiology into the cathlab

October 30, 2026 16:00 ET  | Source: Royal Philips Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced U.S. commercial availability of the HyperVue Integrated System1, a new single room-based configuration of its HyperVue Imaging System for DeepOCT+NIRS imaging and X1-FFR physiology assessment. It is designed

Boehringer Ingelheim registers Phase III trial investigating verducatib in COPD

October 30, 2026 09:37 ET  | Source: Boehringer Ingelheim Ingelheim, Germany and Ridgefield, Conn., U.S. – Boehringer Ingelheim today announced the registration of the Phase III AIRWARD™ trial evaluating its investigational oral therapy verducatib as a treatment option targeting DPP1 in adults with COPD; the trial was published on ClinicalTrials.gov (NCTXXXXXX).1 The trial will evaluate

Asia-Pacific is rapidly gaining importance as a major pillar in global life science innovation

October 30, 2026 05:07 ET  | Source: Boehringer Ingelheim Seoul, Korea – Boehringer Ingelheim today highlighted Asia-Pacific’s increasing importance in global life science innovation. Speaking at the Asia-Pacific Conference of German Business (APK) 2026 in Seoul, Shashank Deshpande, Boehringer Ingelheim Chairman of the Board of Managing Directors, said that “Asia-Pacific is rapidly gaining importance as

Junshi Biosciences Announces the Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS207 in Combination with JS007 for the First-Line Treatment of Advanced Hepatocellular Carcinoma

October 29, 2026 07:04 ET  | Source: Junshi Biosciences SHANGHAI, Oct. 29, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the first patient dosing has been completed in a multi-center, randomized,

Philips launches UniGuide 3D Live Guidance, bringing CT planning into live procedures and extending the capabilities of its Azurion image-guided therapy platform

October 29, 2026 05:00 ET  | Source: Royal Philips October 29, 2026 New CE-marked solution leverages the industry-leading Philips Azurion platform to integrate CT-derived insights and treatment planning directly into the procedural workflow, helping physicians make informed decisions during treatment.Amsterdam, the Netherlands –Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subcutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma

October 28, 2026 20:25 ET  | Source: Junshi Biosciences SHANGHAI, China, Oct. 28, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application for the company’s product, toripalimab

Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer

October 28, 2026 07:00 ET  | Source: Adagene Inc. Phase 1 study to evaluate the combination of muzastotug, a masked anti-CTLA-4 SAFEbody, and INCA33890, Incyte’s TGFβR2 × PD-1 bispecific antibody, in 3L MSS CRC patients with and without liver metastases SAN DIEGO and SUZHOU, China, Oct. 28, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq:

Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026

October 27, 2026 23:48 ET  | Source: Junshi Biosciences SHANGHAI, Oct. 27, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the final analysis results from the Phase 3 NEOTORCH study (NCT04158440)

Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline

October 27, 2026 08:00 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that it has completed the acquisition of assets from BioXcel Therapeutics, Inc., including worldwide rights to BXCL501. BXCL501

Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

October 27, 2026 07:00 ET  | Source: Adagene Inc. SAN DIEGO and SUZHOU, China, Oct. 27, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in a fireside chat and one-on-one meetings at the

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

October 24, 2026 02:30 ET  | Source: Zymeworks Inc. VANCOUVER, British Columbia, Oct. 24, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the randomized dose-optimization portion of its ongoing Phase

Scroll to Top